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Abstract: Medulloblastoma (MB), a primitive neuroectodermal tumor, is the most common malignant childhood brain
tumor and remains incurable in about a third of patients. Currently, survivors carry a significant burden of late treatment
effects. The p53 tumor suppressor protein plays a crucial role in influencing cell survival in response to cellular stress and
while the p53 pathway is considered a key determinant of anti‐tumor responses in many tumors, its role in cell survival in
MB is much less well defined. Herein, we report that the experimental drug VMY‐1‐103 acts through induction of a partial
DNA damage‐like response as well induction of non‐survival autophagy. Surprisingly, the genetic or chemical silencing of
p53 significantly enhanced the cytotoxic effects of both VMY and the DNA damaging drug, doxorubicin. The inhibition of
p53 in the presence of VMY revealed increased late stage apoptosis, increased DNA fragmentation and increased
expression of genes involved in apoptosis, including CAPN12 and TRPM8, p63, p73, BIK, EndoG, CIDEB, P27Kip1 and P21cip1.
These data provide the groundwork for additional studies on VMY as a therapeutic drug and support further investigations
into the intriguing possibility that targeting p53 function may be an effective means of enhancing clinical outcomes in MB.
INTRODUCTION

chemotherapy has contributed to improved treatment
outcomes, resulting in a 70-80% five-year disease-free
patients with medulloblastoma remain significant and
recurrence is frequently observed. As with many malignancies, disease recurrence is nearly always fatal, and late
mortality remains a serious health issue in long-term MB
survivors [2]. Moreover, current therapies result in
significant negative impacts on neurological, cognitive and
social development, especially in the youngest affected
children. Significant efforts are therefore underway to
develop more effective and less toxic MB treatments.

Medulloblastoma (MB) is a primitive neuroectodermal
tumor that arises from granule neuron precursors in the
cerebellum or from neural stem cells of the rhombic lip
and is the most frequently diagnosed malignant brain
tumor in children [1]. Approximately 70% of MB cases
occur in children under the age of 10. While less
common, MB is also seen in patients between 20 and 44
years of age, with incidences falling off significantly
thereafter. A combination of surgery, radiotherapy, and
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The efficacy of many anti-tumor agents relies on their
ability to trigger the tumor suppressive activities of p53,
which leads to the induction of cell death, frequently via
cellular pathways of apoptosis, senescence or mitotic
catastrophe. While the activity of the p53 tumor
suppressor protein is highly complex [3], its expression
is induced by a broad array of cell stressors including
DNA-damaging chemotherapeutic drugs and can be an
excellent target for therapeutic intervention ([4], see
also [3]). Impairment of p53 signaling by gene mutation
or gene silencing/loss has been shown to contribute to
the induction, progression and/or recurrence of many
tumor types and can confer resistance to tumor therapy.
p53 plays unique roles in neural development. For
example, p53 has been directly implicated in
neurogenesis as well as in neural stem cell self-renewal,
neurite outgrowth and axonal regeneration (reviewed in
[5]), and acetylation of p53 is required for the induction
of neurite outgrowth [6]. Despite this knowledge and
that related to the role of p53 in many malignancies, the
function of p53 in MB remains under-explored. For
example, unlike lung, pancreas and bladder cancers,
only a minority of primary MB patients present with
p53 mutation or loss, with reported frequencies between
7% [7] and 15% [8]. Interestingly, while the frequency
of p53 mutations increases upon recurrence, the
percentage of cells with nuclear p53 also increases,
rising from 26% at diagnosis to 33% at relapse [8],
suggesting that certain mechanisms underlying p53
function may still be intact. Importantly, the MAGIC
consortium identified chromosome 17 deletions, where
the p53 locus is located, to be associated with
chromothripsis (chromosomal fragmentation) in Group
3 MB [9], while reduced expression of p53 was seen in
Group 4 MB [10]. Collectively, these findings
highlight the complex and poorly defined role for p53
in human MB, and support the need for mechanistic
studies into p53 activity as a possible therapeutic
effector protein.

Interestingly, suppression of p53 function via shRNA
knockdown or treatment with the p53 inhibitory
compound Pifithrin-α (Pif) [16] resulted in significant
increases in cell death following treatment with either
VMY or doxorubicin. Gene expression analyses
performed on D556 cells treated with VMY and Pif
versus VMY alone revealed a significant increase in
genes associated with apoptosis and necrosis, including
the calcium pathway signaling genes CAPN12 and
TRPM8 suggesting alterations in intracellular calcium
signaling may play a role in enhancing cell death. In
addition, p63 and its transcriptional target the proapoptotic gene BIK were induced, as were p73 and its
target, the caspase-independent intranucleosomal
DNase, Endonuclease-G (Endo-G) [17].
Given the difficulties in effectively treating MB,
especially recurrent disease, targeting p53 in
combination with chemotherapy potentially represents a
new treatment strategy for medulloblastoma.

RESULTS
Treatment of MB cells induces a durable cytotoxic
effect
We have previously reported that VMY induces MB cell
death [12, 14]. To test whether VMY’s antiproliferative
effects were sustained after removal of the compound,
colony forming assays were performed. D556 cells were
treated with VMY or its parent compound purvalanol B
(PVB) for 18 hrs, at which point the media was changed
and the cells were allowed to recover in the absence of
the drugs until the control plate reached 80% confluency
(approximately 3-5 days). VMY treatment resulted in a
significant reduction in both the number of colonies (Fig
1A, B, C) as well as the number of cells per colony (Fig
1D) versus either DMSO- or PVB- treated D556 cells,
which express wild type p53. The DNA damaging drug,
doxorubicin (1uM), effectively killed all cells (not
shown).

The in vitro [11-13] and in vivo [14] anti-tumor
activities of an experimental CDK inhibitor, VMY-1103 (VMY), have previously been described by us in
both prostate and other solid tumors [11, 13, 15] and in
MB [12, 14]. Our previous MB studies established that
the extrinsic apoptotic pathway was induced by VMY,
as was mitotic catastrophe in a subset of the cells [12].
In the present study, we sought to further define the
molecular and genetic mechanisms by which VMY
induces MB cell death. Herein, we show in both p53wild type (D556) and p53-mutant (DAOY) MB cells
lines that treatment with VMY resulted in the
translocation of p53 into the nucleus, an induction of
γH2AX, a decrease in MDM2 protein levels and
activation
of
non-survival
macro-autophagy.
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VMY induces a partial DNA damage-like response
in DAOY and D556 MB cell lines
Our previous studies established that the induction of
cell death in MB cells occurred, at least in part, through
the extrinsic apoptotic pathway and mitotic disruption
[12, 14]. To further investigate the mechanisms by
which VMY impacts cell survival, we interrogated
proteins involved in DNA damage response and stress
signaling. Time course studies of VMY treatment were
performed first in DAOY cells, which express mutant
p53 (p53C252F). Doxorubicin was used as a positive
control for induction of a DNA damage response [18],
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Figure 1. VMY induced cell death. The durability of effects of VMY on cell viability was determined via colony forming assays.
D556 cells were treated with DMSO, PVB or VMY for 18 hrs. Fresh media was added and the cells cultured for an additional 3‐5 days.
(A) Cells stained with crystal violet. (B) Colonies as visualized by microscopy. (C) Quantification of colony number. (D) Quantification
of cells per colony. The data are shown as average + standard deviation. PVB; purvalanol B, *; p<0.05.

Figure 2. Effects of VMY on stress related proteins. DAOY cells were treated for 18 hrs with
DMSO, PVB, VMY or doxorubicin at the concentrations listed and immunoblotting was performed
for the proteins shown. β‐actin was used as a loading control. PVB; purvalanol B, Doxo; doxorubicin.
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and PVB was also tested. Compared to DMSO control,
treatment with doxorubicin for 18 hours increased the
levels of phosphorylated isoforms of ATM, Chk2,
γH2AX, BRCA1 and p38 (Fig. 2) as well as ATR,
pS46-p53 and Chk1 (Fig 2). A modest increase in
mTOR was also noted. In contrast, the levels of all of
these proteins, with the exception of p-γH2AX (Fig 2)
and to a lesser extent mTOR, were reduced following
treatment with VMY. Interestingly, PVB behaved in a

manner similar to doxorubicin despite the fact that PVB
is an inefficient inhibitor of MB cell proliferation [12].
In contrast to DAOY cells, the levels of total- and
phospho- p38 remained relatively constant in D556
cells and phospho-p38 decreased slightly following 18
hrs of VMY treatment (Fig 3A), however sustained
induction of γH2AX was confirmed by western blot and
by immunofluorescence in both DAOY and D556 cells
(Fig 3A, B).

Figure 3. Effects of VMY on stress related proteins in MB cells. DAOY and D556 cells were treated with PVB or VMY. (A)
Immunoblotting was performed for total and phosphorylated p38 and phosphorylated γ‐H2AX following treatment for 6 or 18
hrs. (B) Immunofluorescence microscopy for γ‐H2AX was performed on DAOY cells treated with 1 uM doxorubicin for 18 hrs and
DAOY and D556 cells treated with 10 uM VMY for 18 hrs. DAPI was used to stain the nuclei. PVB; purvalanol B, Doxo; doxorubicin.

Figure 4. Induction of Autophagy by VMY reduces cell
viability. (A) D556 cells, transfected with LC3‐GFP,
were treated with DMSO or VMY for 4 and 18 hrs.
Autophagic LC3‐GFP puncta were visualized by
fluorescence microscopy. Cell nuclei were stained with
DAPI. (B) D556 and (C) DAOY cells were treated with
VMY for 18hrs in the presence or absence of 5 uM 3‐
MA (an inhibitor of early autophagy) or 50 uM
chloroquine (an inhibitor of acidification of lysosomes
and autophagosomes), and trypan blue viability assays
were performed to establish cell viability. The data are
shown as the average + standard deviation of N=3
separate experiments. *; p<0.05, **; p<0.01, 3‐MA; 3‐
methyladenine, CQ; chloroquine.
.
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VMY induces autophagy in MB cells

Regulation of p53 activity is similar in DAOY and
D556 MB cell lines

VMY has the ability to block proliferation in prostate
cancer cells in part through the induction of catastrophic
autophagy [15]. During autophagy, LC3-I (microtubuleassociated protein 1 light chain 3) becomes lipidated by
the class III phosphoinositide 3-kinase, Vps34, and relocalizes from the microtubules to autophagosomal
membranes (reviewed in Kang, et al. [19]). We
therefore studied the pattern of subcellular localization
of LC3-I in MB cells. D556 cells were transiently
transfected with an LC3-GFP expression vector and
subjected to fluorescence microscopy as previously
described [15]. VMY treatment induced LC3-GFP relocalization and concentration into prototypical
autophagic puncta (Fig 4A) with an average of 6 puncta
per VMY-treated, LC3-GFP positive cell at 4 hours and
7.8 puncta per cell at 18 hrs, versus an average of 2.3
puncta per cell in control cells (Fig 4A). Our previous
data established that inhibition of autophagy protected
against VMY-induced cell death in prostate cancer cells
[15]. We therefore investigated whether inhibitors of
early (3-methyladenine, 3-MA) or late (chloroquine,
CQ) autophagy influenced cell survival. Using D556
and DAOY cells, trypan blue dye exclusion assays
established that neither 3-MA nor CQ influenced
survival in control cells, however significant increases
(p<0.05, N=3 separate experiments) in cell viability
were seen in both cell lines when treated with VMY and
the inhibitors (Fig 4B, C).

Our earlier investigations into the mechanisms by which
VMY reduced overall cell survival in solid tumors
clearly established a role for wild type p53 in inducing
cell death through both apoptosis and catastrophic
autophagy. For example, in adenocarcinoma cell lines
with wild type p53, VMY caused a rapid induction of
p53 protein levels whereas p53 levels remained constant
in cells harboring p53 mutations [15]. Furthermore, the
loss of p53 function via deletion, mutation or genetic
silencing resulted in a complete loss of VMY-induced
cytotoxicity in a variety of cancers, including prostate,
breast and pancreas, while re-expression of wild type
p53 in PC3 cells or treatment of DU145 cells with
PRIMA1 restored VMY-induced autophagy and cell
death [11, 15].
We therefore next investigated the effects of VMY on
p53 expression in DAOY (p53 C242F mutant [20]) and
D556 cells (p53 wild type). Unlike our previous
findings in adenocarcinoma cells, p53 levels were high
in both cell lines and were not affected by treatment
with VMY (Supplemental Fig. 1). Similar results were
seen with PVB (Supplemental Fig. 1). The levels of the
p53-regulatory protein MDM2 were decreased in both
cell lines (Fig 5A) and immunofluorescence microscopy
demonstrated that p53 shifted from diffusely cytoplasmic with some nuclear positivity in control cells to

Figure 5. VMY alters the subcellular localization of p53. (A) Immunoblotting for MDM2 following exposure of D556 cells to
PVB and VMY for the times indicated. β‐actin was used as a loading control. (B) Immunofluorescence microscopy for p53 subcelluar
localization was performed on DAOY (left panels) and D556 (right panels). DAPI was used to stain the nuclei. PVB; purvalanol B.

www.impactaging.com

858

AGING, October 2015, Vol. 7 No.10

predominantly nuclear in both cell lines following
VMY treatment (Fig 5B). As both the wild type and
mutant p53 proteins localize to the nucleus following
exposure to VMY, these data suggest that both proteins
may retain some functional activity.

in up to a 68% decrease in p53 protein levels versus
pLKO control across all treatment groups in both D556
and DAOY cells (Fig 6A). Surprisingly, both the genetic
and chemical silencing of p53 led to significant increases
in cell death by VMY as measured by colony forming
assay (Fig 6B). Equally surprising was the observation
that the loss of p53 failed to protect against cell death by
doxorubicin (Fig 6B, C). Dose escalation experiments
performed in D556 cells in the presence and absence of
Pif established that the heightened chemosensitivity was
consistent across a broad range of concentrations (Fig
6D). In addition, experiments performed in DAOY
showed that cell-survival declined by 33 percent in
VMY-treated cells with p53 shRNA knockdown compared to VMY-treated pLKO control cells (Sup Fig S2).

The role of p53 in inducing cell death
To determine the role of p53 in regulating MB cell
survival in the presence of VMY, p53 was genetically
silenced with the previously validated p53 shRNA [15] or
chemically inhibited by the p53-inhibitory compound,
Pifithrin-α (Pif), which we have used in previous
experiments to investigate p53’s role in regulating
autophagy [16]. The silencing of p53 by shRNA resulted

Figure 6. Effects of silencing of p53 on cell survival. (A) Genetic silencing of p53. D556 and DAOY cells were infected with
p53siRNA or pLKO lentivirus’. The cells were left untreated or exposed for 18 hrs to DMSO or 30uM VMY as indicated, and western
blots for p53 and β‐actin were run. (B) The effects of p53shRNA knockdown (left) and Pifithrin (Pif, right) on cell viability were
determined via colony forming assays. D556 cells were treated with DMSO, doxorubicin or VMY for 18 hrs. Fresh media was added
and the cells cultured for an addition 3‐5 days, followed by staining with crystal violet. (C) Quantification of the number of colonies in
(B). (D) Dose response curves of D556 cells treated with VMY at the concentrations shown in the presence and absence of Pifithrin.
The data are shown as average + standard deviation of N=3 separate experiments.
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Table 1. Top 25 genes altered in the presence of Pifithrin α plus VMY
vs. VMY alone.
Pif + VMY vs. VMY
Up-regulated

Fold

EndoG
CIDEB
PRSS54
BIK
MAP3K9
ERBB3
BRAT1
CISH
FADD
TP63
CBX6
SRC
CBX7
HDAC4
RASSF4
TRPM8
ERBB2
AKT1
UNC5B
TNFRSF10D
NLRP12-14
TP73
ARHGEF18
TNFRSF25
FASTK

8.77809E+30
1.9687E+12
1299.03
19.44
18.19
15.17
7.48
6.73
6.73
6.63
6.23
5.98
5.98
5.24
4.49
4.49
4.06
3.84
3.83
3.74
3.74
3.74
3.55
3.49
3.48

Down-regulated
FIGF
ANGPT4
GSK3A
INCA1
TNFSF14
GDF15
HGF
BIRC3
LIF
NTF3
DRD2
SNCG
MAGEA9
ZNF385D
CRIP3
TNFSF15
NAP1L6
TENC1
NRCAM
DNAJB7
MAGEB2
PPAPDC2
PRSS12
CFLAR
GADD45A

Loss of p53 in the presence of VMY alters calcium,
p63 and p73 signaling pathways

-6.10476E+11
-6.017072518
-5.35
-5.18
-4.01
-4.01
-3.89
-3.41
-2.85
-2.77
-2.75
-2.67
-2.67
-2.67
-2.67
-2.45
-2.45
-2.33
-2.23
-2.21
-2.19
-2.14
-2.14
-2.07
-2.07

[21, 22]), with one of the hallmarks of necrosis being
Endo G induction and intranucleosomal DNA cleavage
[22]. As both the pro-apoptosis regulatory genes p63 and
p73 were induced by p53 silencing, as were possible
downstream targets including Endo-G [23], the proapoptotic BH3-protein, BIK (Bcl-2-interacting killer) and
CIDEB (cell death-inducing DFFA-like effector B), we
assessed levels of late stage apoptosis and necrosis by
flow cytometry, by gating for annexin Vpositive/propidium iodide (PI)-positive cells. D556 cells
were infected with either pLKO or p53shRNA as
described above and treated for 18-hours with DMSO,
30uM VMY or 1uM doxorubicin, after which they were
analyzed by flow cytometry as previously described [15].
+
While the annexin /PI fraction of cells was unaffected,
the silencing of p53 increased the proportion of annexin
V+/PI+ cells following exposure to VMY or doxorubicin

In order to more completely define the mechanism
underlying the paradoxical effect of p53 silencing,
RNAseq next generation sequencing was performed on
D556 cells treated with VMY in the presence or
absence of Pif. RNA sequence analysis revealed an
increase in expression of calpain 12 in the VMY/Pif
treated cells vs. VMY/DMSO control cells (Table 1). In
addition, elevated expression of the transient receptor
potential channel subfamily (TRPM8) gene was seen
(Table 1), collectively suggesting that intracellular
calcium signaling pathways were affected by p53
silencing. Dysregulation of the calcium signaling
pathway downstream of stressors such as excitotoxicity
can lead to necrotic cell death in neurons (reviewed in
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Figure 7. Effects of p53 knockdown on apoptosis and DNA fragmentation in D556 cells. (A) The proportion of
cells undergoing apoptotic cell death as a result of p53 shRNA knockdown in D556 cells treated for 18 hrs with DMSO,
VMY (30uM) or doxorubicin (1uM) as assessed using annexin V and propidium iodide (PI) staining and measured by flow
cytometry. Data are shown as percent change in staining versus pLKO‐control infected cells. (B) D556 cells were infected
with pLKO or p53shRNA and treated with DMSO, VMY or doxorubicin for 18hrs. DNA fragmentation of nuclear DNA was
assessed by ethidium bromide‐agarose gel electrophoresis.

(Fig 7A). Finally, similar effects were seen using
agarose gel electrophoresis assays where 18-hour
treatment with VMY or doxorubicin plus p53shRNA
resulted in enhanced DNA degradation, indicative of
necrosis and apoptosis (Fig 7B).

on MB established that this experimental drug induced
apoptosis and mitotic catastrophe in vitro [12].
Furthermore, while our in vivo studies showed that 20
mg/kg of VMY administered three times per week for
more than four weeks was well tolerated and was
effective at treating a mouse model of SHH-driven
medulloblastoma [14], a detailed investigation into the
mechanism of VMY-induced cell death, and the role that
p53 may play had not been explored. We now show that
in MB cells, VMY induces the relocalization of p53 into
the nucleus, an accumulation of γH2AX, a decrease in
MDM2 protein levels and activation of non-survival
macro-autophagy. Since the protein levels of key stressrelated proteins were reduced by VMY, the possibility
existed that components of the CAP-dependent protein
translation pathway may be inhibited by VMY. MNK1 is
a target of p38 and MAPK and acts to increase CAPdependent translation through the phosphorylation of the
elongation factor eIF4E [28]. 4E-BP1 is a negative
regulator of translation and phosphorylation of 4E-BP1
by mTOR inhibits its repressor function. Thus, if VMY
negatively regulated CAP-dependent translation, the
phosphorylation levels of 4E-BP1 and pMNK1 would be
expected to reduce, however VMY increased the levels
of these proteins in both D556 and DAOY cells (S.W and
C.A, unpublished data). Interestingly, rather than
protecting against chemotherapeutic cell killing, the
suppression of p53 through shRNA knoc kdown or
chemical inhibition by Pifithrin-α resulted in a significant
increase in cell death by either VMY or doxorubicin,
suggesting that p53 acts as a chemoprotective protein in
these primitive neuroectoderm-derived cancer cells.

Taken together, these experiments show that p53
protects against drug-induced cell death in
medulloblastoma cells and its genetic- or chemicalsuppression results in a significant increase in cell
sensitivity to VMY and doxorubicin, an experimental
and a clinical drug, respectively.

DISCUSSION
Necrosis, apoptosis and autophagy are activated under a
variety of cell stress conditions (see references [24, 25]
among others), however, little is known about how
these complex and partially overlapping mechanisms
are induced in medulloblastoma cells. In addition, to
date, there have been few publications exploring the
effects in medulloblastoma cells of the synthetic
modulation of p53 activity during exposure to
chemotherapeutic drugs.
We have recently shown in prostate cancer cell lines as
well as in primary prostate cancer cells established
using our conditional cell reprogramming approach [26,
27], that the induction of p53 by VMY was a
prerequisite for inducing both autophagy and apoptosis,
and that silencing p53 effectively blocked cell death
[15]. Additionally, our earlier studies on VMY’s effects
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Regarding its function in the neuroectoderm, p53
performs roles different to those found in other tissues.
In the past decade a role for p53 has emerged in
neuronal differentiation, axon guidance, neurite
outgrowth and axonal regeneration [29, 30]. Analysis of
p53-dependent transcriptional activation in normal
development in vivo by using a lacZ reporter gene under
the control of a p53-responsive promoter showed that
p53 activity was maximal during neuronal
differentiation and clustered in areas that showed little
correlation with the apoptosis normally ongoing in the
developing nervous system [31, 32]. Furthermore, other
studies have shown that approximately one quarter of

p53-null mice developed exencephaly due to cellular
overgrowth, rather than decreased apoptosis [33, 34].
The dependence of neurite outgrowth and elongation on
p53 has also been shown in the developing cerebellum.
Gaub et al., 2010 showed that acetylated p53 is required
for neurite outgrowth in cerebellar granule cell
progenitors. Conversely, the loss of the function acetyl
p53 mutant (K-R) inhibits physiological neurite
outgrowth in those cells [35]. In cultured rat cerebellar
granule cells, Maruoka et al., 2011, showed a p53mediated neuroprotective effect against glutathione
depletion-induced oxidative stress [36].

Figure 8. Proposed mechanisms of enhanced cell death following inhibition of p53. Shown are the effects of p53 suppression on
components of cell death pathways in Pif + VMY vs. VMY treated D556 cells. p53 inhibition by Pifithrin resulted in the induction of p63 and
p73 genes and subsequent enhanced cell death via apoptosis. Induction of the p63 and p73 genes leads to the activation of p21CIP1 and
p27KIP1 both of which can indirectly trigger FADD, reducing the expression of BIRC3 (cIAP2). Induction of p73 led to large increases in EndoG
and CIDEB expression leading to DNA fragmentation while increased levels of p63 induced apoptosis though BIRC3 and BIK, the latter of
which along with TRPM8 can influence intracellular calcium levels. BAD; BCL2‐Associated Agonist Of Cell Death, BIK; BCL2‐Interacting Killer
(Apoptosis‐Inducing), BIRC3; baculoviral IAP repeat containing 3 (cIAP2), BRAT1; BRCA1‐Associated ATM Activator 1, CAPN; Calpain, CALB1;
Calbindin 1, CDKN2D; Cyclin‐Dependent Kinase Inhibitor 2D (p19Ink4D), CIDEB; Cell Death‐Inducing DFFA‐Like Effector B, EndoG;
Endonuclease G, FADD; Fas‐Associated Via Death Domain, INCA1; Inhibitor Of CDK, Cyclin A1 Interacting Protein 1, NF‐KappaB; Nuclear
Factor Of Kappa Light Polypeptide Gene Enhancer In B‐Cells, TRPM8, Transient receptor potential cation channel subfamily M member 8.
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Further validation of the role for p53 in neurite
outgrowth and neuronal differentiation and maturation
comes from studies establishing p53 as a downstream
target of neurotrophic receptors. Loss of function
experiments of p53 via either gene silencing or
dominant negative p53 proteins lacking transactivation
capacity have been shown to block NGF-dependent
neurite outgrowth and differentiation in PC-12 cells [6,
37]. Another neurotrophic factor, BDNF, has also been
shown to stimulate p53 phosphorylation and
transcriptional activation in primary cortical neurons
[30]. Activation of signaling molecules downstream of
NGF or BDNF that are known to induce p53 posttranslational
modifications
and
enhance
its
transcriptional activity has been reported, including
ERK1 and ERK2, p38MAPK, JNK1-2 (c-Jun Nterminal kinases 1-2), cytoskeleton remodeling genes,
such as GAP-43, the actin-binding protein Coronin 1b
and the RAS family member Rab13 [6, 38].

function by either shRNA knockdown or Pif sensitized
DAOY and D556 cells to both VMY and doxorubicin.
Mechanistically, the induction of the p63 and p73 and
their targeted genes by VMY in the Pif-treated cells was
one of the most prominent features (Table 1 and Figure
8). These p53 family-member genes, and their various
splice variants, play both similar and distinct roles in
development as well as in cancer (reviewed in [45]) and
can interact with each other with a high degree of
complexity. There is abundant evidence that modulation
of p53 function can influence the activity of p63 and
p73 (reviewed in [46]) and conversely that p63 and p73
can influence p53 activity in adult neural precursor cells
[47]. While the mechanism(s) by which the genetic
knockdown or chemical suppression of p53 regulates
p63 and p73 expression in MB cells has yet to be
elucidated, our data suggest that the induction of p63
and p73 following p53 suppression fundamentally alters
the pro-apoptotic machinery in MB cells (Fig 8). It is
also unknown whether the increased sensitivity seen in
the cell lines tested extends to a broader array of clinical
samples or to the chemo-radiation interventions
currently used for treating MB. However as both
DAOY and D556 cells show similar sensitivities to p53
functional blockade, the possibility exists that at least a
subset of the p53 mutations found in MB patients may
not adversely impact p53-targeting regimens.
Additional experiments assessing whether the p53
mutant proteins identified in recurrent MB exhibit
similar responses to combined p53 suppression and
exposure to VMY, doxorubicin or other drugs are
clearly warranted.

Unresolved however is an actual role for p53 in the
biology of human MB. Frequencies of p53 mutations are
low in primary MB but increase significantly in
recurrences, and mutant p53 proteins and Myc may
collaborate to drive aggressive disease [8]. Additionally,
modifications of p53 function are required in Myc- [39,
40] but not Smoothened- based mouse models to drive
MB. The genetic silencing of p53 in mice with
conditional deletion of the BRCA2-interacting protein
(BCCIP) gene also resulted in MB [41]; however the
resulting tumor formation was predicated upon the loss of
the BCCIP knockdown cassette, which restored BCCIP
expression in the neuroectoderm, supporting a role for
p53 in neuronal genomic stability. Interestingly, p53
expression levels are lower in group 4 MB, due to the
iso-dicentric (17)(p11.2) recombination events frequently
seen in this group [10]. However, neither the levels of
p53 expression nor its subcellular localization were
reported following chemotherapy. It should be noted that
etoposide induced p53 activity in D283, MEDI and D458
MB cell lines in vitro [42] and the p53 target miR-34a
was able to reduce the viability in the p53-impared MB
cell line, MEB-Med8a [43], however the effects of
silencing of p53 per se were not reported. Furthermore,
docosahexaenoic acid and etoposide were found to
reduce the levels of MDM2 in both p53-mutant DAOY
cells as well as in p53-wildtype D283 cells [44] and we
also observe decreases in MDM2 with VMY, along with
rapid translocation of p53 into the nucleus. Collectively
these published studies and our new data suggest that
components of the p53 pathway remain intact in a variety
of p53-mutant and p53-wild type MB cells.

MATERIALS AND METHODS
Cell lines and cell culture. The human medulloblastoma
(MB) cell lines D556 and DAOY were maintained in
complete DMEM containing 10% FBS, L-glutamine,
and 100 U/ml Penicillin-Streptomycin as previously
described [12]. DNA STR fingerprint analyses were
performed on both cell lines as a quality control
measure. The DAOY data matched the ATCC database
for this line, while early and late passage D556 cultures
were compared with no significant changes observed
and no matches with the available STR database (not
shown).
Cell viability and growth. Cell viability was determined
using trypan blue dye exclusion and viable and total cell
counting using a hemocytometer as previously
described [11, 12, 15].
Colony forming assays. A total of 1000 cells were
plated in 6 well plates. Cells were allowed to adhere for
24 hrs before treatment, at which point they were

It was therefore surprising that rather than causing
chemotherapeutic resistance, the suppression of p53
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treated with VMY or Doxorubicin for 18 hrs. The media
was changed after 18hrs and the plates were incubated
in the absence of drug for 3-5 days to reach 80%
confluency in the negative control wells. Cells were
washed with PBS, fixed with 10% neutral buffered
formalin solution for 15-30 minutes and stained with
0.5% (w/v) crystal violet for 30-60 minutes. The crystal
violet was aspirated, cells were washed with PBS and
dried for one hour before counting.

hr at room temperature. The slides were washed with
PBS an additional three times and stained with the
secondary antibody Alexa Fluor goat 488 anti-mouse
(1:150, Life Technologies, A-10667) for 30 min at room
temperature. Slides were then counter-stained with
DAPI for 5 min. The coverslips were mounted onto
glass slides with Tris-buffered fluoro-gel (Electron
Microscopy Sciences). Confocal microscopy was
performed on a Zeiss (Thornwood, NY) LSM510 Meta
microscope using a 40x lens.

Flow cytometry. The prostate cells were fixed and
stained with 20ug/ml propidium iodide (PI) and 5 U
RNase A, and the DNA content and subG1 DNA
fragmentation was measured using a FACStar Plus
system (Becton-Dickson, Franklin Lakes, NJ) as
previously described [11, 12]. Cellular apoptosis was
also assessed by APC-Annexin V antibody (Biolegend,
San Diego, CA) staining immediately after treatment
with VMY and analyzed using FACStar Plus dual laser
FACSort system (Becton-Dickson, Franklin Lakes, NJ)
as previously described by us [11, 12, 48, 49].

LC3-GFP. LC3 translocation was detected using the
green fluorescent protein (GFP)-fused LC3 construct
that was generously donated by Dr Robert Clarke [51].
Briefly, cells were seeded in 6 well plates containing
glass coverslips and allowed to attach overnight. The
LC3-GFP expression plasmid (14ug) was transfected
using Lipofectamine LTX reagent (Life Technologies,
Carlsbad, CA #15338-100) as previously described by
us [15]. 24 hours after transfection, the cells were
treated with VMY or vehicle. After 18 hours, the
coverslips with attached cells were stained with DAPI
and rinsed 3 times with PBS and the coverslips
mounted. Imaging was performed by confocal
microscopy as previously described [12, 15].

Immunoblotting. Protein extracts were prepared and
separated on 4-20% Tris-glycine gels and electroblotted onto PVDF membranes as previously described
[11, 12, 50]. Protein levels were assessed using
antibodies against p53 (Millipore, Bellerica, MA #05224), p-ATM (Cell Signaling, Danvers, MA #5883P),
p-Chk2 (Cell Signaling, Danvers, MA #2661P), p-Chk1
(Cell Signaling, Danvers, MA #2348P), p38 (Cell
Signaling, Danvers, MA #8690), histone γ-H2AX (Cell
Signaling, Danvers, MA #7631), p-histone γH2AX
(Cell Signaling, Danvers, MA #9718P), p-BRCA1
(Ser1524) (Cell Signaling, Danvers, MA #9009P), pP38 MAPK (Cell Signaling, Danvers, MA #9216S),
mTOR (Cell Signaling, Danvers, MA #2983), p-ATR
(Cell Signaling, Danvers, MA #2853P), p-p53 (Cell
Signaling, Danvers, MA #9286P), p-MNK1 (cell
signaling, #2111S), p-4E-BP1 (Cell Signaling, Danvers,
MA #2855S), MDM2 (Santa Cruz Biotechnology, #sc965), β-actin (Cell Signaling, Danvers, MA #4967).
Densitometry was performed using ImageJ analysis
software (NIH, Bethesda, MD) as previously described
[11, 12, 50].

Autophagy inhibitors. For autophagy inhibition, 3methyladenine (3-MA) (Sigma-Aldrich, St Louis, MO
#M921) was used at 5mM and chloroquine diphosphate
(CQ) (Sigma-Aldrich, St Louis, MO #C6628) was used
at 50 µM as previously described [15]. Cells were
exposed to these inhibitors for 20 minutes prior to
treatment with either DMSO or VMY [15].
p53 expression and shRNA knockdown. For lentivirus
knockdown experiments, the p53shRNA and pLKO
vectors were purchased commercially (Vector Biolabs,
Philadelphia, PA, #1854) and used as described by the
manufacturer as previously described [15]. Briefly,
293T cells (ATCC, Manassas, VA) were cotransfected
with shRNA constructs along with the pHR′8.2ΔR and
pCMV-VSV-G helper constructs. After 24 hours, the
media was changed and the virus-containing media was
harvested after an additional 24 hours of incubation.
The MB cells were seeded at 30% confluency and viral
infections were performed for 72 hours prior to treatment
with VMY or DMSO. Efficiency of the knockdown was
monitored by p53 immunoblotting and quantification by
ImageJ as previously described [15, 52, 53].

Immunofluorescent imaging. Cells were seeded on glass
coverslips and treated with DMSO or VMY for 4 or 18
hrs. Cells were washed with PBS and fixed in 10%
formalin for 10 min. The coverslips were washed three
times with PBS, the cells were permeabilized with 0.1%
Triton X-100 and washed three times with PBS. The
samples were blocked with 1% BSA for 20 minutes and
washed an additional three times in PBS. The cells were
exposed to anti-p53 (1:150, Millipore #05-224) or antiγH2AX (1:150, Cell Signaling #7631) antibodies for 1
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Chemical inhibition of p53. For chemical inhibition of
p53, 30uM Pifithrin-α (Sigma-Aldrich, St Louis, MO
#P4359) was added one hour prior to treatment with
VMY, doxorubicin or DMSO.
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DNA fragmentation. D556 cells were infected with
pLKO or p53shRNA virus’s for 72 hrs prior to
treatment with VMY or DMSO. Doxorubicin was used
as a positive control. The genomic DNA was isolated
after 18 hr treatment with VMY or doxorubicin using
the DNeasy blood and tissue kit (Qiagen, MD #69506).
500ng of DNA was run on 1% agarose gel containing
ethidium bromide with the electrophoresis carried out at
100V for one hour.
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RNAseq and pathway analyses. Total RNA was
extracted from D556 cells treated with Pif and VMY as
described above using an RNeasy Plus Mini Kit
(Qiagen, MD, #74134) and submitted to Otogenetics
Corporation (Norcross, GA USA) for RNA-Seq assays.
Sequencing was performed on the Illumina HiSeq 2500
(20 million reads, Rapid run, Illumina, CA USA) with
chemistry v1.0 and using the 2×106bp paired-end read
mode and original chemistry from Illumina according to
the manufacturer's instructions. The initial data analysis
was started directly on the HiSeq 2500 System during
the run. The HiSeq Control Software 2.0.5 in
combination with RTA 1.17.20.0 (real time analysis)
performed the initial image analysis and base calling.
Quality control (QC) was performed using FastQC
software. All the samples passed the "Basic Statistics",
"Per Base Sequence Quality", "Per Sequence Quality
Scores", "Per Base N Content", and "Sequence Length
Distribution". No specific filtering was done for the
samples. The final FASTQ files comprising the
sequence information which was used for all subsequent
bioinformatics analyses. Sequences were demultiplexed according to the 6bp index code with 1
mismatch allowed. After QC, Tophat2 was used for the
alignment, and BAM files were obtained. Partek
Genomics Suite (6.6 version 6.12.0713 software (Partek
Inc.) was utilized to calculate RPKM as normalization,
and fold changes were calculated based on the RPKM
results. The pathways analysis was performed through
the use of QIAGEN’s Ingenuity® Pathway Analysis
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SUPPLEMENTAL FIGURES

Supplemental Figure S1. Immunoblotting for p53 following exposure of D556 cells to PVB and VMY for the times
indicated. b‐actin was used as a loading control. MWM (kDa); molecular weigh marker in kilodaltons.

Supplemental Figure S2. Infection of MB cells with pLKO or p53shRNA. Three days
after infection, DAOY cells were either left untreated or exposed to DMSO or VMY for
18 hrs. Cell viability was determined by trypan blue dye exclusion. The data are shown
as average + standard deviation of N= 2 separate experiments. *; p < 0.05.
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